$GOVX
GeoVax Labs, Inc. Stock $govx

$govx Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000143774922026579 Filed on November 09, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$0.00	$0.00	$30.41K
YoY Change	-100.0%	-100.0%	-92.68%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.623M	$1.249M	$757.4K
YoY Change	59.97%	64.94%	72.14%
% of Gross Profit
Research & Development	$3.765M	$2.721M	$1.224M
YoY Change	-70.8%	122.25%	193.78%
% of Gross Profit
Depreciation & Amortization	$14.07K	$17.67K	$8.940K
YoY Change	20.15%	97.65%	-189.4%
% of Gross Profit
Operating Expenses	$5.388M	$3.971M	$1.982M
YoY Change	-61.27%	100.35%	132.67%
Operating Profit		-$3.971M	-$1.951M
YoY Change		103.47%	347.25%
Interest Expense	$3.690K	$0.00	$0.00
YoY Change	398.65%		-100.0%
% of Operating Profit
Other Income/Expense, Net		$2.431K	$877.00
YoY Change		177.19%	-100.65%
Pretax Income	-$5.384M	-$3.968M	-$1.951M
YoY Change	-60.83%	103.44%	242.19%
Income Tax
% Of Pretax Income
Net Earnings	-$5.384M	-$3.968M	-$1.951M
YoY Change	-60.83%	103.44%	241.8%
Net Earnings / Revenue			-6413.17%
Basic Earnings Per Share		-$0.17	-$0.31
Diluted Earnings Per Share	-$0.20	-$169.1K	-$307.2K
COMMON SHARES
Basic Shares Outstanding	26.33M	24.74M	6.328M
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$27.61M	$34.68M	$18.11M
YoY Change	141.71%	91.51%	56.36%
Cash & Equivalents	$27.61M	$34.68M	$18.11M
Short-Term Investments
Other Short-Term Assets	$1.326M	$1.460M	$52.82K
YoY Change	748.69%	2664.5%	428.2%
Inventory
Prepaid Expenses
Receivables	$0.00	$0.00	$0.00
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$28.94M	$36.14M	$18.16M
YoY Change	148.85%	99.0%	54.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$234.9K	$249.0K	$168.7K
YoY Change	49.68%	47.63%	1570.99%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.174M	$2.184M	$11.01K
YoY Change	19648.28%	19739.11%	10.1%
Total Long-Term Assets	$2.409M	$2.433M	$179.7K
YoY Change	1334.49%	1254.35%	751.36%
TOTAL ASSETS
Total Short-Term Assets	$28.94M	$36.14M	$18.16M
Total Long-Term Assets	$2.409M	$2.433M	$179.7K
Total Assets	$31.35M	$38.57M	$18.34M
YoY Change	165.73%	110.31%	56.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.748M	$1.079M	$289.4K
YoY Change	-15.06%	272.94%	79.24%
Accrued Expenses	$3.000M	$3.710M	$46.21K
YoY Change	-11.18%	7928.18%	-92.03%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$4.748M	$4.789M	$335.7K
YoY Change	-12.65%	1326.9%	-63.66%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$0.00	$2.000M
YoY Change	-100.0%
Total Long-Term Liabilities	$0.00	$2.000M	$0.00
YoY Change	-100.0%		-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.748M	$4.789M	$335.7K
Total Long-Term Liabilities	$0.00	$2.000M	$0.00
Total Liabilities	$4.748M	$6.789M	$335.7K
YoY Change	-36.14%	1922.76%	-64.37%
SHAREHOLDERS EQUITY
Retained Earnings	-$78.40M	-$73.01M	-$50.63M
YoY Change	21.78%	44.2%	13.86%
Common Stock	$105.0M	$104.8M	$68.64M
YoY Change	52.75%	52.68%	24.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$26.60M	$31.78M	$18.00M
YoY Change
Total Liabilities & Shareholders Equity	$31.35M	$38.57M	$18.34M
YoY Change	165.73%	110.31%	56.0%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$5.384M	-$3.968M	-$1.951M
YoY Change	-60.83%	103.44%	241.8%
Depreciation, Depletion And Amortization	$14.07K	$17.67K	$8.940K
YoY Change	20.15%	97.65%	-189.4%
Cash From Operating Activities	-$7.064M	-$3.799M	-$1.634M
YoY Change	5.7%	132.55%	483.46%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$51.88K	-$27.79K
YoY Change		86.69%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	-$51.88K	-$27.79K
YoY Change		86.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	7.626M	230.0K
YoY Change		3215.45%	-97.94%
NET CHANGE
Cash From Operating Activities	-7.064M	-3.799M	-1.634M
Cash From Investing Activities	0.000	-51.88K	-27.79K
Cash From Financing Activities	0.000	7.626M	230.0K
Net Change In Cash	-7.064M	3.775M	-1.431M
YoY Change	5.7%	-363.68%	-113.16%
FREE CASH FLOW
Cash From Operating Activities	-$7.064M	-$3.799M	-$1.634M
Capital Expenditures	$0.00	-$51.88K	-$27.79K
Free Cash Flow	-$7.064M	-$3.747M	-$1.606M
YoY Change	5.7%	133.34%	473.54%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0000832489
	dei	Entity Registrant Name EntityRegistrantName	GeoVax Labs, Inc.
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26334953
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26334953
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6381541
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6381541
CY2021Q4	us-gaap	Other Liabilities OtherLiabilities	2000000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y8M12D
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39563
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-0455038
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1900 Lake Park Drive, Suite 380
	dei	Entity Address City Or Town EntityAddressCityOrTown	Smyrna
	dei	Entity Address State Or Province EntityAddressStateOrProvince	GA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	30080
	dei	City Area Code CityAreaCode	678
	dei	Local Phone Number LocalPhoneNumber	384-7220
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	26334953
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34676968	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11423870	usd
CY2021Q4	us-gaap	Grants Receivable GrantsReceivable	49006	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1460207	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	156240	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	36137175	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	11629116	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	248983	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	156938	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2184286	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11010	usd
CY2022Q3	us-gaap	Assets Assets	38570444	usd
CY2021Q4	us-gaap	Assets Assets	11797064	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1079421	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2057534	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3709984	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3377826	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4789405	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5435360	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2000000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2000000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	6789405	usd
CY2021Q4	us-gaap	Liabilities Liabilities	7435360	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	26335	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	6382	usd
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	104767918	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	68731220	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-73013214	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-64375898	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	31781039	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	4361704	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	38570444	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11797064	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	30414	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	81526	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	220539	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2721196	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1224362	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5358917	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2659980	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1249337	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	757432	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3363672	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2562641	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	3970533	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	1981794	usd
	us-gaap	Operating Expenses OperatingExpenses	8722589	usd
	us-gaap	Operating Expenses OperatingExpenses	5222621	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3970533	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1951380	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8641063	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5002082	usd
CY2022Q2	govx	Stock Issued During Period Value Warrant Exercise StockIssuedDuringPeriodValueWarrantExercise	567	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	72000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	190191	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2241699	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	27872657	usd
CY2022Q3	govx	Stock Issued During Period Value Warrant Exercise StockIssuedDuringPeriodValueWarrantExercise	7625543	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	60750	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	190191	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3968102	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	2431	usd
CY2021Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	877	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	3747	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	3998	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	-0	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	-0	usd
	us-gaap	Interest Expense InterestExpense	-0	usd
	us-gaap	Interest Expense InterestExpense	1286	usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	172056	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2431	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	877	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3747	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	174768	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3968102	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1950503	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8637316	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4827314	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.63
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.80
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23461665
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6349297
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13818315
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6005032
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	4361704	usd
CY2022Q1	govx	Stock And Warrants Issued During Period Value Common Stock And Warrants StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants	9229248	usd
CY2022Q1	govx	Stock Issued During Period Value Warrant Exercise StockIssuedDuringPeriodValueWarrantExercise	24	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	190191	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2427515	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	11353652	usd
CY2022Q2	govx	Stock And Warrants Issued During Period Value Common Stock And Warrants StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants	18497946	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	31781039	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	9568852	usd
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9408920	usd
CY2021Q1	govx	Stock Issued During Period Value Warrant Exercise StockIssuedDuringPeriodValueWarrantExercise	3174156	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	6000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	56190	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-1562778	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	20651340	usd
CY2021Q2	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	1000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	65841	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	56190	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1314033	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	19458338	usd
CY2021Q3	govx	Stock Issued During Period Value Warrant Exercise StockIssuedDuringPeriodValueWarrantExercise	230000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	56190	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	209825	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1950503	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	18003850	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8637316	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4827314	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	42213	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	26806	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	209825	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	172056	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-49006	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-182663	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1251539	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-106979	usd
	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	-2173276	usd
	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	0	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-645955	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-289477	usd
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-3328656	usd
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	314043	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11965972	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4513271	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	134258	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	47718	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-134258	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-47718	usd
	govx	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	27727194	usd
	govx	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	9408920	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	7626134	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3404156	usd
	us-gaap	Payments For Repurchase Of Convertible Preferred Stock PaymentsForRepurchaseOfConvertiblePreferredStock	-0	usd
	us-gaap	Payments For Repurchase Of Convertible Preferred Stock PaymentsForRepurchaseOfConvertiblePreferredStock	1000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	-0	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	27864	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	35353328	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12784212	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	23253098	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8223223	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11423870	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9883796	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	34676968	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18107019	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">1.</em></b> <b>Nature of Business </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax Labs, Inc., headquartered in the Atlanta, Georgia metropolitan area, is a clinical-stage biotechnology company incorporated under the laws of the State of Delaware. GeoVax Labs, Inc. and its wholly owned subsidiary, GeoVax, Inc., a Georgia corporation, are collectively referred to as “GeoVax” or the “Company”.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company is focused on developing immunotherapies and vaccines against infectious diseases and cancers using novel vector vaccine platforms. GeoVax’s product pipeline includes ongoing human clinical trials for vaccines against COVID-<em style="font: inherit;">19</em> and a therapy for advanced head and neck cancer. Additional research and development programs include preventive vaccines against hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa Fever) and malaria, as well as immunotherapies for solid tumors.</p>
CY2022Q3	govx	Prepaid Clinical Trial Expenses Current PrepaidClinicalTrialExpensesCurrent	1231337	usd
CY2021Q4	govx	Prepaid Clinical Trial Expenses Current PrepaidClinicalTrialExpensesCurrent	0	usd
CY2022Q3	us-gaap	Prepaid Insurance PrepaidInsurance	143450	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	123248	usd
CY2022Q3	us-gaap	Prepaid Rent PrepaidRent	13045	usd
CY2021Q4	us-gaap	Prepaid Rent PrepaidRent	13045	usd
CY2022Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	72375	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	19947	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1460207	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	156240	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	841417	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	707159	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	592434	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	550221	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	248983	usd
CY2022Q3	govx	Noncancellable Obligations NoncancellableObligations	1200000	usd
CY2022Q3	us-gaap	Unrecorded Unconditional Purchase Obligation Balance Sheet Amount UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount	612000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	156938	usd
CY2022Q3	govx	Prepaid Clinical Trial Expenses Noncurrent PrepaidClinicalTrialExpensesNoncurrent	2083276	usd
CY2021Q4	govx	Prepaid Clinical Trial Expenses Noncurrent PrepaidClinicalTrialExpensesNoncurrent	0	usd
CY2022Q3	govx	Prepaid Technology License Fees PrepaidTechnologyLicenseFees	90000	usd
CY2021Q4	govx	Prepaid Technology License Fees PrepaidTechnologyLicenseFees	0	usd
CY2022Q3	us-gaap	Security Deposit SecurityDeposit	11010	usd
CY2021Q4	us-gaap	Security Deposit SecurityDeposit	11010	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2184286	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11010	usd
CY2022Q3	govx	Accrued License Fees Current AccruedLicenseFeesCurrent	3000000	usd
CY2021Q4	govx	Accrued License Fees Current AccruedLicenseFeesCurrent	3000000	usd
CY2022Q3	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	0	usd
CY2021Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	269000	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	709984	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	108826	usd
CY2022Q3	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	3709984	usd
CY2021Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	3377826	usd
CY2022Q3	us-gaap	Other Liabilities OtherLiabilities	2000000	usd
CY2022Q3	govx	Licensing Agreement Future Minimum Payments Receivable Current LicensingAgreementFutureMinimumPaymentsReceivableCurrent	409000	usd
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	13384115
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	849571	usd
CY2022Q3	govx	Prepaid Expense Value Of Stock Issued For Services During Period PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod	72375	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	238566	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	85750	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	650895	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	249303	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14346415
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3418631

Files In Submission

Name	View Source	Status
0001437749-22-026579-index-headers.html	Edgar Link	pending
0001437749-22-026579-index.html	Edgar Link	pending
0001437749-22-026579.txt	Edgar Link	pending
0001437749-22-026579-xbrl.zip	Edgar Link	pending
ex_442043.htm	Edgar Link	pending
ex_442044.htm	Edgar Link	pending
ex_442045.htm	Edgar Link	pending
ex_442046.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
govx-20220930.xsd	Edgar Link	pending
govx20220930_10q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
govx-20220930_cal.xml	Edgar Link	unprocessable
govx-20220930_def.xml	Edgar Link	unprocessable
govx-20220930_lab.xml	Edgar Link	unprocessable
govx-20220930_pre.xml	Edgar Link	unprocessable
govx20220930_10q_htm.xml	Edgar Link	completed
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GOVX
GeoVax Labs, Inc. Stock $govx

2022 Q4 Form 10-Q Financial Statement

#000143774922026579 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GOVX GeoVax Labs, Inc. Stock $govx

2022 Q4 Form 10-Q Financial Statement

#000143774922026579 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GOVX
GeoVax Labs, Inc. Stock $govx